Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Reversible pulmonary hypertension associated with multivisceral Whipple's disease

Alice Camboulive, Etienne-Marie Jutant, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Charlotte Mussini, Jérémie Bénichou, Jean-Christophe Lagier, Marc Humbert, David Montani
European Respiratory Journal 2021 57: 2003132; DOI: 10.1183/13993003.03132-2020
Alice Camboulive
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
9Contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne-Marie Jutant
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
9Contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Savale
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Savale
Xavier Jaïs
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Sitbon
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Sitbon
Charlotte Mussini
4AP-HP, Service d'Anatomie et de Cytologie Pathologiques, Hôpital de Bicêtre, Le Kremlin Bicêtre, France
5Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérémie Bénichou
5Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
6AP-HP, Service d'ophtalmologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Christophe Lagier
7Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France
8IHU-Méditerranée Infection, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Humbert
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
David Montani
1Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
2Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
3INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Montani
  • For correspondence: david.montani@aphp.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A report of multivisceral Whipple's disease with severe precapillary pulmonary hypertension cured by doxycycline and hydroxychloroquine therapy associated with initial oral combination of bosentan and tadalafil. https://bit.ly/2SECU3L

To the Editor:

Whipple's disease (WD) is a rare infectious disease developed through fecal–oral transmission and caused by Tropheryma whipplei, a ubiquitous gram bacillus [1]. The pathogenesis remains unclear, and several host factors seem to be implicated, including male sex, comorbidities and genetic susceptibility [1]. WD is a multivisceral disorder with frequent gastro-intestinal, joint and neurological involvement, as well as pulmonary, cardiovascular, mucocutaneous and ophthalmologic lesions [2]. The diagnosis is made via small bowel biopsy with periodic acid Schiff staining (PAS) positivity and by PCR on different biological samples [1]. Classical treatment requires prolonged antibiotic therapy and allows rapid improvement. Combination therapy with doxycycline and hydroxychloroquine over 1 year followed by lifetime treatment with doxycycline has been shown to lead to good clinical responses and fewer relapses [3]. Others have recommended initial use of intravenous antibiotics, followed by trimethoprim–sulfamethoxazole for 1 year [4]. Among lung complications of WD, pulmonary hypertension (PH) is very rare and remains poorly understood [5–8]. Here, we report the first well-documented case of a man with concomitant diagnosis of severe precapillary PH and multivisceral WD who had total reversibility in haemodynamics and clinical state after treatment of WD and PH.

A 54-year-old Caucasian man, a technician for phonelines and former smoker (18 pack-years), with a medical history of gastro-oesophageal reflux and systemic hypertension treated by beta-blockers, was hospitalised for acute right heart failure in the respiratory intensive care unit. He reported a deterioration in general state over the previous year with fatigue, a weight loss of 15 kg, diarrhoea, a change in mood and episodes of acute left red eye with spontaneous resolution. In April 2019, he presented to the emergency department with progressive dyspnoea that had been worsening for a few weeks. Clinical examination showed signs of right heart failure, biology showed a microcytic anaemia and increased N-terminal pro-B-type natriuretic peptide (NT-proBNP), and transthoracic echocardiography showed dilation of the right heart chambers, increased estimated systolic pulmonary artery pressure (65 mmHg) and right ventricular dysfunction (tricuspid annular plane systolic excursion 12 mm). Computed tomography pulmonary angiography revealed right heart dilation, with no evidence of acute pulmonary embolism and normal lung parenchyma (figure 1). He had no family history or exposures to drugs and toxins. Right heart catheterisation (RHC) confirmed severe precapillary PH without acute pulmonary vasodilator response to inhaled nitric oxide: mean pulmonary artery pressure (mPAP) 40 mmHg, cardiac output 3.1 L·min−1, cardiac index 2 L·min−1·m−2, pulmonary artery wedge pressure 13 mmHg and pulmonary vascular resistance (PVR) 8 WU. Treatment with intravenous dobutamine and diuretics was initiated together with oral dual combination of pulmonary arterial hypertension (PAH) drugs (bosentan and tadalafil). Evolution was favourable, and dobutamine was stopped after 5 days. Clinical investigations found no evidence for other conditions associated with group 1 PAH (such as connective tissue disease, congenital heart disease, portal hypertension or HIV infection), group 3 PH due to chronic respiratory diseases, or group 4 chronic thromboembolic PH (normal ventilation–perfusion scan). Because of the associated weight loss, diarrhoea and microcytic anaemia, a gastroscopy was performed, and duodenal biopsies showed infiltration of the lamina propria by foamy PAS-positive macrophages (figure 1). As gastroscopy can be a high risk procedure in patients with PH, it was performed in the intensive care unit with a mild sedation and careful medical supervision. T. whipplei PCR was positive in the saliva but negative in the cerebrospinal fluid. He also presented a congestive left eye with ptosis, exophthalmia, conjunctival injection, moderate visual loss and periorbital inflammation with limited eye movements and increased intraocular pressure (figure 1). Orbital magnetic resonance imaging confirmed left exophthalmia and inflammatory pseudo-tumour of the left orbit (figure 1). Doxycycline (100 mg twice per day) and hydroxychloroquine (200 mg three times per day) were started. After 2 months, the patient's evolution was remarkable: he experienced great improvements in his general state (weight gain of 13 kg in 9 months), with total correction of all initial symptoms. Repeated haemodynamic measurements (at 5, 9 and 14 months) showed a complete correction of PH (mPAP <20 mmHg, PVR <3 WU), and bosentan and tadalafil were sequentially stopped without recurrence of PH. 14 months after diagnosis and 5 months after interruption of PAH therapy, he had no exercise limitations in New York Heart Association functional class I, with 610 m 6-min walk distance and a peak oxygen uptake at 85% of the theoretical maximum (26.4 mL·kg−1·min−1), with normal biological markers, including NT-proBNP (141 pg·mL−1). C-reactive protein (CRP), which was 107 mg·L−1 at the diagnosis, remained <5 mg·L−1 during the follow-up. He continued on combined doxycycline and hydroxychloroquine for 1 year and will continue doxycycline for life to prevent WD relapses. He had no side-effects from the treatments, and repeated ECG showed no QT interval prolongation with hydroxychloroquine.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Main characteristics of the patient at the diagnosis of Whipple's disease. a) Diffuse and massive infiltration of the lamina propria by foamy and pink macrophages (haemotoxylin, eosin and safran, original magnification ×100). b) Periodic acid-Schiff-positive macrophages with round bacterial inclusions in the lamina propria (original magnification ×200). c) CD68-positive macrophages in the lamina propria (Agilent, clone PG-M1 1/200, original magnification ×200). d) Axial contrast-enhanced high-resolution computed tomography image of the mediastinum showing right atrium and ventricle dilation. e) Photograph showing the left congestive eye associated with proptosis, periorbital inflammation and lateral deviation. f) Orbital magnetic resonance imagery in T2-weighted imaging showing left exophthalmia and a hypersignal of the left orbit consistent with an inflammatory pseudo-tumour.

In the literature, we found 10 case reports of PH associated with WD, not always confirmed by RHC [5–7]. Six cases were well documented with evidence of precapillary PH [7]. Among these 10 patients, 80% had favourable evolution with antibiotic therapy (intravenous beta-lactam antibiotics followed by trimethoprim–sulfamethoxazole in six cases and doxycycline associated with hydroxychloroquine in the remaining two) [6–8]. Three patients were prescribed calcium channel blockers (associated with phosphodiesterase type 5 inhibitor in one), but this therapy failed with worsening of symptoms, even in the case with acute response to vasodilators [7]. One patient died after a valve replacement for aortic insufficiency [7]. The haemodynamic evolution after treatment was well documented by RHC in only two patients [7].

Our patient is the first reported case with favourable outcomes of WD and PH after treatment with doxycycline and hydroxychloroquine associated with initial oral combination of bosentan and tadalafil [9]. The pathophysiology of precapillary PH in WD remains unclear. Pulmonary artery infiltration by T. whipplei in the tunica media has been suspected, along with small pulmonary artery obliteration by macrophages and fibrinoid debris [10]. Our present case of excellent clinical and haemodynamic outcomes with WD therapy argue in favour of reversible pulmonary vascular involvement. One hypothesis for this reversible vascular involvement may be an excessive inflammation and dysregulated immunity response in the pulmonary vascular wall, as observed in systemic arteries with signs of arteritis [11] and in intestinal cells, with down-regulation of MHC class II promoting local accumulation of bacteria and inflammation [12] and consistent with the decrease in CRP during the follow-up in our patient.

In conclusion, we report a case of multivisceral WD with severe precapillary PH cured by doxycycline and hydroxychloroquine therapy associated with initial oral combination of bosentan and tadalafil. PH did not relapse after weaning from bosentan and tadalafil. Based on this remarkable evolution, also observed in other case reports, the causal link between WD and PH appears strong, even if data are currently insufficient to provide a thorough understanding of the mechanisms leading to PH in that setting [13]. Based on this case and a literature review, we propose to classify PH associated with WD within group 5 PH with unclear and/or multifactorial mechanisms [14].

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-03132-2020.Shareable

Footnotes

  • Conflict of interest: A. Camboulive has nothing to disclose.

  • Conflict of interest: E-M. Jutant has nothing to disclose.

  • Conflict of interest: L. Savale has nothing to disclose.

  • Conflict of interest: X. Jais has nothing to disclose.

  • Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion, Bayer and MSD, personal fees from Acceleron, Ferrer and Gossamer Bio, grants from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: C. Mussini has nothing to disclose.

  • Conflict of interest: J. Bénichou has nothing to disclose.

  • Conflict of interest: J-C. Lagier has nothing to disclose.

  • Conflict of interest: M. Humbert reports grants and personal fees from Actelion and Bayer Heathcare, personal fees from Acceleron, GSK, Merck, Novartis, AstraZeneca and Sanofi, outside the submitted work.

  • Conflict of interest: D. Montani reports grants and personal fees from Actelion, Bayer Heathcare, MSD and GlaxoSmithKline, outside the submitted work.

  • Received August 13, 2020.
  • Accepted October 6, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Marth T,
    2. Moos V,
    3. Müller C, et al.
    Tropheryma whipplei infection and Whipple's disease. Lancet Infect Dis 2016; 16: e13–e22. doi:10.1016/S1473-3099(15)00537-X
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lagier J-C,
    2. Lepidi H,
    3. Raoult D, et al.
    Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine 2010; 89: 337–345. doi:10.1097/MD.0b013e3181f204a8
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Lagier J-C,
    2. Fenollar F,
    3. Lepidi H, et al.
    Treatment of classic Whipple's disease: from in vitro results to clinical outcome. J Antimicrob Chemother 2014; 69: 219–227. doi:10.1093/jac/dkt310
    OpenUrlCrossRefPubMed
  4. ↵
    1. Feurle GE,
    2. Junga NS,
    3. Marth T
    . Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. Gastroenterology 2010; 138: 478–486. doi:10.1053/j.gastro.2009.10.041
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Riemer H,
    2. Hainz R,
    3. Stain C, et al.
    Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease. Thorax 1997; 52: 1014–1015. doi:10.1136/thx.52.11.1014
    OpenUrlAbstract
  6. ↵
    1. Brevet P,
    2. Rottenberg P,
    3. Viacroze C, et al.
    A case of Whipple's disease mimicking auto-inflammatory disease and revealed by severe right cardiac failure under anakinra. Joint Bone Spine 2020; 87: 365–366. doi:10.1016/j.jbspin.2019.11.004
    OpenUrl
  7. ↵
    1. Baloira A,
    2. Núñez M,
    3. Tumbeiro M, et al.
    Pulmonary hypertension associated with Whipple disease. Eur Respir Rev 2014; 23: 533–536. doi:10.1183/09059180.00005714
    OpenUrlFREE Full Text
  8. ↵
    1. Lochouarn M,
    2. Lagier J-C,
    3. Raoult D, et al.
    A case of Whipple's disease evolving over 30 years. Med Mal Infect 2014; 44: 331–333. doi:10.1016/j.medmal.2014.06.002
    OpenUrl
  9. ↵
    1. Galiè N,
    2. Channick RN,
    3. Frantz RP, et al.
    Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889. doi:10.1183/13993003.01889-2018
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. James TN,
    2. Bulkley BH
    . Whipple bacilli within the tunica media of pulmonary arteries. Chest 1984; 86: 454–458. doi:10.1378/chest.86.3.454
    OpenUrlCrossRefPubMed
  11. ↵
    1. James TN,
    2. Haubrich WS
    . De subitaneis mortibus. XIV. Bacterial arteritis in Whipple's disease. Circulation 1975; 52: 722–731. doi:10.1161/01.CIR.52.4.722
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ectors NL,
    2. Geboes KJ,
    3. De Vos RM, et al.
    Whipple's disease: a histological, immunocytochemical, and electron microscopic study of the small intestinal epithelium. J Pathol 1994; 172: 73–79. doi:10.1002/path.1711720112
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Humbert M,
    2. Guignabert C,
    3. Bonnet S, et al.
    Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019; 53: 1801887. doi:10.1183/13993003.01887-2018
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Simonneau G,
    2. Montani D,
    3. Celermajer DS, et al.
    Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. doi:10.1183/13993003.01913-2018
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reversible pulmonary hypertension associated with multivisceral Whipple's disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Reversible pulmonary hypertension associated with multivisceral Whipple's disease
Alice Camboulive, Etienne-Marie Jutant, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Charlotte Mussini, Jérémie Bénichou, Jean-Christophe Lagier, Marc Humbert, David Montani
European Respiratory Journal Feb 2021, 57 (2) 2003132; DOI: 10.1183/13993003.03132-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Reversible pulmonary hypertension associated with multivisceral Whipple's disease
Alice Camboulive, Etienne-Marie Jutant, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Charlotte Mussini, Jérémie Bénichou, Jean-Christophe Lagier, Marc Humbert, David Montani
European Respiratory Journal Feb 2021, 57 (2) 2003132; DOI: 10.1183/13993003.03132-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society